

Table SI. Summary of individual clinical trials targeting CLDN18.2 included in this review.

Trial ID	Trial phase	Disease	Sponsor/ collaborator type	Primary tested drug	Primary tested drug: Target	Primary tested drug: Therapeutic class	Start date	Country
686850	III	Oncology: Esophageal; gastric	Industry, all other pharma	JS-107	Claudin 18	Anticancer, immunological	2025/12/20	China
685398	I/II	Oncology: Esophageal; gastric	Unassigned	ATG-022	Claudin 18	Anticancer, other	Planned	China
665149	I	Oncology: Pancreas	Academic	Givastomig	Claudin 18; TNF receptor Superfamily member 9	Anticancer, immunological	Planned	United States
665148	I	Oncology: Gastric	Academic	Givastomig	Claudin 18; TNF receptor superfamily member 9	Anticancer, immunological	Planned	Japan
663695	I	Oncology: Bile duct (cholangiocarcinoma)	Industry, all other pharma	QLS-31905 pembrolizumab, Qilu Pharmaceutical	CD3 epsilon subunit of T-cell receptor complex; claudin 18 programmed cell death 1	Anticancer, immunological	Planned	China
662208	II	Oncology: Bile duct (cholangiocarcinoma)	Industry, all other pharma	QLS-31905 pembrolizumab, Qilu Pharmaceutical	CD3 epsilon subunit of T-cell receptor complex; claudin 18 programmed cell death 1	Anticancer, immunological	2025/9/1	China
X652857	III	Oncology: Esophageal; gastric	Industry, all other pharma	IMC-002, Suzhou Immunofoco Biotechnology	Claudin 18	Anticancer, immunological	2025/8/6	China
644193	II	Oncology: Gastric; metastatic cancer	Academic	Paclitaxel zolbetuximab-clzb tislelizumab tegafur-uracil	Epidermal growth factor receptor; erb-b2 receptor tyrosine kinase 2; tubulin beta class I claudin 18 programmed cell death 1	Anticancer, other Anticancer, immunological Anticancer, antimetabolite	2025/7/1	China
580884	II	Oncology: Esophageal; gastric	Industry, all other pharma	Capecitabine tegafur + CDHP + oxonic acid zolbetuximab-clzb oxaliplatin	Thymidylate synthetase thymidylate synthetase claudin 18	Anticancer, antimetabolite Anticancer, immunological Anticancer, alkylating	2024/12/6	Japan
576583	II	Oncology: Esophageal; gastric	Academic	Zolbetuximab-clzb	Claudin 18	Anticancer, immunological	2025/4/14	Japan
574845	II	Oncology: Esophageal; gastric	Academic	Paclitaxel ramucirumab zolbetuximab-clzb	Epidermal growth factor receptor; erb-b2 receptor tyrosine kinase 2; tubulin beta class I kinase insert domain receptor claudin 18	Anticancer, other Anticancer, immunological	2025/12/11	Belgium
571941	II	Oncology: Esophageal; gastric	Industry, all other pharma	QLS-31905 pembrolizumab, Qilu Pharmaceutical	CD3 epsilon subunit of T-cell receptor complex; claudin 18 programmed cell death 1	Anticancer, immunological	2025/5/28	China
554077	II	Oncology: Esophageal; gastric	Academic	Zolbetuximab-clzb	Claudin 18	Anticancer, immunological	2024/9/20	Japan
543585	I	Unspecified solid tumor	Industry, all other pharma	HD-004	Claudin 18	Anticancer, immunological	Planned	China
535875	II	Oncology: Esophageal; gastric	Academic	Cadonilimab tecotabart vedotin	Cytotoxic T-lymphocyte associated protein 4; programmed cell death 1 claudin 18	Anticancer, immunological	2024/7/31	China
520339	II	Oncology: Bile duct (cholangiocarcinoma); esophageal; gastric; unspecified solid tumor	Industry, all other pharma	Iparomlimab + tuvonralimab QLS-31905	Cytotoxic T-lymphocyte associated protein 4; programmed cell death 1 CD3 epsilon subunit of T-cell receptor complex; claudin 18	Anticancer, immunological	2024/6/30	China
515191	I	Oncology: Pancreas	Industry, all other pharma	Zolbetuximab-clzb	Claudin 18	Anticancer, immunological	2025/9/24	United States
511775	III	Oncology: Esophageal; gastric	Industry, all other pharma	tecotabart vedotin	Claudin 18	Anticancer, immunological	2024/6/18	China
511570	I/II	Oncology: Esophageal; gastric; unspecified solid tumor	Industry, all other pharma	SHR-A1904	Claudin 18; DNA topoisomerase I	Anticancer, other	2024/5/29	China
507231	I	Oncology: Esophageal; gastric	Industry, generic	Enlonstobart EO-3021	Programmed cell death 1 claudin 18	Anticancer, immunological	Planned	China
507230	III	Oncology: Esophageal; gastric	Industry, generic	Enlonstobart EO-3021	Programmed cell death 1 claudin 18	Anticancer, immunological	2024/11/28	China
501473	II	Oncology: Esophageal; gastric	Academic Industry, all other pharma	Catequentinib benmelstobart	Fibroblast growth factor receptor-4; fms related tyrosine kinase 4; kinase insert domain receptor; vascular endothelial growth factor A CD274 molecule	Anticancer, immunological; respiratory	2024/2/25	China

500141	III	Oncology: Esophageal; gastric	Industry, all other pharma	ASKB-589	Claudin 18	Anticancer, immunological	2024/1/12	China
495753	I	Unspecified solid tumor	Industry, all other pharma	AK-132	CD47 molecule; claudin 18	Anticancer, immunological	2025/1/5	China
492640	I	Oncology: Gastric; pancreas; unspecified solid tumor	Academic Industry, all other pharma	KD-496	Claudin 18; killer cell lectin like receptor K1	Anticancer, immunological	2024/3/4	China
488652	I	Oncology: Esophageal; gastric; pancreas; unspecified solid tumor	Academic	CLDN18.2/PD-L1 dual-targeting CAR-T therapy, unspecified	Claudin 18; programmed cell death 1	Anticancer, immunological	2024/1/1	China
486176	I/II	Oncology: Bile duct (cholangiocarcinoma); esophageal; gastric; pancreas; unspecified solid tumor	Industry, all other pharma	QLS-31905	CD3 epsilon subunit of T-cell receptor complex; claudin 18	Anticancer, immunological	2023/10/1	China
482813	I	Oncology: Gastric; pancreas; unspecified solid tumor	Industry, all other pharma	Claudin 18.2 targeting ADC, Luzsana Biotechnology	Claudin 18; DNA topoisomerase I	Anticancer, other	Planned	
482257	I/II	Oncology: Esophageal; gastric; pancreas; unspecified solid tumor	Industry, Top 20 pharma	AZD-5863	CD3 epsilon subunit of T-cell receptor complex; claudin 18	Anticancer, immunological	2023/7/11	China; France; Japan; Netherlands; South Korea; United Kingdom; United States
480517	I	Oncology: Anal; bile duct (cholangiocarcinoma); colorectal; esophageal; gallbladder; gastric; liver; small intestine	Academic Industry, Top 20 pharma	AZD-6422	Claudin 18	Anticancer, immunological	2023/12/14	China
476921	I	Unassigned	Unassigned	Intravenous injection of 68Ga-PMD22			2023/5/28	China
476562	II	Oncology: Anal; bile duct (cholangiocarcinoma); colorectal; esophageal; gallbladder; gastric; liver; pancreas; small intestine	Industry, all other pharma	tecotabart vedotin	Claudin 18	Anticancer, immunological	2023/7/21	China
467808	I	Oncology: Esophageal; gastric; pancreas; unspecified solid tumor	Academic	IMC-008	Unspecified	Anticancer, immunological	2023/4/2	China
451224	I	Oncology: Esophageal; gastric; lung, non-small cell; pancreas; unspecified solid tumor	Industry, all other pharma	SG-1906	CD47 molecule; claudin 18	Anticancer, immunological	Planned	China
448711	I	Oncology: Esophageal; gastric	Industry, all other pharma Industry, Top 20 pharma	AB-011	Claudin 18	Anticancer, immunological	Planned	China
447439	I	Oncology: Bile duct (cholangiocarcinoma); esophageal; gastric; pancreas	Industry, all other pharma	LM-102	Claudin 18	Anticancer, immunological	Planned	China
445444	I	Oncology: Gastric; pancreas; unspecified solid tumor	Academic Industry, all other pharma	KD-496	Claudin 18; killer cell lectin like receptor K1	Anticancer, immunological	2022/10/13	China
441805	I	Oncology: Unspecified solid tumor	Industry, Top 20 Pharma	GC-506	Claudin 18	Anticancer, immunological	Planned	China
437829	I	Oncology: Esophageal; gastric; ovarian; pancreas	Industry, all other pharma Academic	IMC-002, Suzhou Immunofoco Biotechnology	Claudin 18	Anticancer, immunological	2022/8/8	China
436045	I	Oncology: Esophageal; gastric; pancreas	Academic	CLDN18.2 dual antibody, unspecified		Anticancer, immunological; Anticancer, other	Planned	Japan
435740	(N/A)	Unassigned	Unassigned	18F-fludeoxyglucose		Miscellaneous	2022/6/23	China
430208	I	Oncology: Bile duct (cholangiocarcinoma); breast; esophageal; gastric; lung, non-small cell; lung, small cell; neuroendocrine; ovarian; pancreas; unspecified solid tumor	Industry, all other pharma	BC-007, Dragonboat Biopharmaceutical	CD47 molecule; claudin 18	Anticancer, immunological	2023/3/27	China
429683	I	Oncology: Esophageal; gastric; unspecified solid tumor	Industry, all other pharma	BC-008	Claudin 18	Anticancer, immunological	2022/8/4	China
423192	I	Oncology: Esophageal; gastric; pancreas	Industry, all other pharma	IBI-345	Claudin 18	Anticancer, immunological	2021/12/13	China
421883	II	Oncology: Bile duct (cholangiocarcinoma)	Academic Industry, all other pharma	Osemitamab	Claudin 18	Anticancer, immunological	2022/1/14	China

419432	I/II	Oncology: Bile duct (cholangiocarcinoma); esophageal; gastric; pancreas	Industry, all other pharma	Tecotabart vedotin	Claudin 18	Anticancer, immunological	2021/11/26	China
415553	II	Oncology: Esophageal; gastric	Industry, all other pharma	Satricabtagene autoleucel	Claudin 18	Anticancer, immunological	2023/5/18	China; United States
410464	(N/A)	Unassigned	Unassigned	89Zr-NY005			2021/8/1	China
409128	I	Oncology: Pancreas	Industry, all other pharma	LY-011	Claudin 18	Anticancer, immunological	2021/8/1	China
407560	I/II	Oncology: Bile duct (cholangiocarcinoma); esophageal; gastric; ovarian; pancreas; unspecified solid tumor	Industry, all other pharma Academic	LM-102	Claudin 18	Anticancer, immunological	2021/10/6	China
395930	I	Oncology: Bile duct (cholangiocarcinoma); colorectal; esophageal; gastric; ovarian; pancreas; unspecified solid tumor	Industry, all other pharma	LM-102	Claudin 18	Anticancer, immunological	2021/5/27	United States
389191	I	Oncology: Esophageal; gastric	Academic Industry, all other pharma	CLDN18.2 UCAR-T cell therapy, Suzhou Maximum Bio-tech	Claudin 18	Anticancer, immunological	2021/1/1	China
371591	I/II	Oncology: Bile duct (cholangiocarcinoma); bladder; colorectal; esophageal; gastric; lung, non-small cell; ovarian; pancreas; unspecified solid tumor	Industry, all other pharma	BNT-141	Claudin 18	Anticancer, immunological	2022/1/18	Canada; Denmark; Germany; Netherlands; Portugal; Spain; United Kingdom; United States
363589	I	Oncology: Esophageal; gastric; pancreas; unspecified solid tumor	Industry, all other pharma Academic	AB-011	Claudin 18	Anticancer, immunological	2020/6/4	China
347971	I/II	Oncology: Gastric	Academic Industry, all other pharma	CLDN18.2/CD19 targeted chimaeric antigen receptor-T cell therapy, innovative cellular therapeutics	CD19 molecule; claudin 18	Anticancer, immunological	2019/8/9	China
272301	I	Oncology: Pancreas; unspecified solid tumor	Industry, all other pharma	BNT-212	Claudin 18	Anticancer, immunological	2019/12/1	
170545	II	Oncology: Esophageal; gastric	Industry, all other pharma	Zolbetuximab-clzb	Claudin 18	Anticancer, immunological	2012/7/19	Bulgaria; Czech Republic; Germany; Latvia; Russia; Ukraine
132381	II	Oncology: Pancreas	Industry, all other pharma	Zolbetuximab-clzb	Claudin 18	Anticancer, immunological	2019/3/15	Australia; Brazil; China; United Kingdom; United States